• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23290 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of ambulatory electrocardiography technologies for the diagnosis of cardiac arrhythmia]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation and impact of a primary care-based telemonitoring intervention in home care patients with heart failure or chronic lung disease. Randomised controlled trial. The TELBIL study]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluating the implementation of diagnostic telemedicine in the field of dermatology]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluating the health service and inequality in the health insurance coverage expansion for cancer; Before and after study: Part 2: Evaluation of the impact in inequality before and after the enhancement of health insurance coverage of cancer]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluating the health service and inequality in the health insurance coverage expansion for cancer; Before and after study: Part 1: Evaluation of the change in medical services before and after the enhancement of health insurance coverage of cancer]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etrasimod (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [ETIAMEST I & II: Highlights]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Addendum]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation]
2014     Canary Health Service [Estimation of the set of values for the health states of the EQ-5D-5L based on the preferences of the Spanish population]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Estimation of incidence of urinary incontinence associated with pregnancy and childbirth]
2003     Center for Medical Technology Assessment (CMT) [Estimating health care need]
2013     Andalusian Health Technology Assessment Area (AETSA) [Esteem® totally implantable hearing device for treatment of sensorineural hearing loss. Systematic review]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Establishing standards, records and analytical procedures for the treatment of ulcerative colitis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Addendum to Commission A21-25]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin/sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Addendum to Commission A21-158]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (liposarcoma) - Addendum A16-31
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (Addendum to Commission A14-25)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Erenumab in migraine prevention]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2009     Committee for New Health Technology Assessment (CNHTA) [ERCC1 RNA RT-PCR quantification]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eravacycline (complicated intra-abdominal infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus VCA IgA]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus EA IgA]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Epoetin (EPO) for anaemic cancer patients]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Epileptic source localization with EEG-correlated functional MRI]
2018     Andalusian Health Technology Assessment Area (AETSA) [Epigenetic profile for the identification of primary cancer of unknown origin]
2018     Canary Health Service [Epidermal growth factor for the treatment of diabetic foot ulcers]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Epidermal growth factor (Heberprot-P®) in chronic ulcers]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Epidemiology of long COVID: a preliminary report. German short version of the original KCE report]
2003     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Epidemiology and costs of osteoarthritis and rheumatoid arthritis in Hungary]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Epidemiological analysis of information collected by hospital cancer registries in the Basque Autonomous Community. Identification of possible improvements with regard to the feedback and dissemination of results]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzyme replacement therapy in mucopolysaccharidoses I, II and VI; 2011]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzymatic replacement treatment for type I gaucher's disease patients]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A21-77]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A18-80]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Addendum to Commission A20-75]
2011     Committee for New Health Technology Assessment (CNHTA) [Enterovirus real-time rt-pcr]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Enhancing the quality of information on colorectal and prostate cancer in the population cancer register of the Basque Country (RCE) and bibliographical review]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial carcinoma) - Addendum to Commission A22-61]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - 2nd addendum to commission A22-61]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Endovenous laser therapy for varicose veins in the lower extremities]
2022     HTA South [Endovascular valve repair in severe mitral insufficiency]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endovascular treatment of varicose veins by radiofrequency ablation or cyanoacrylate closure]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2016     Haute Autorite de sante (HAS) [Endovascular thrombectomy of intracranial arteries]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke. National Report: German Summary of the correspondent EUnetHTA Report]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair of thoracic and thoraco-abdominal aortic aneurysm]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular repair of aortic aneurysms]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair in abdominal aortic aneurysm]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment versus saphenectomy for the management of varicose veins in lower limbs]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment of varicose veins of the lower limbs]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Addendum to commission H20-08]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Endovascular contra open surgical treatment of symptom generating atherosclerotic lesions of the external iliac artery]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endothelial cell count in subjects who underwent laser photorefractive surgery for myopia or keratoplasty for keratoconus]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Endoscopic tri-modal imaging for improved detection of early neoplasia in the gastrointestinal tract]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermoablation of the duodenal mucosa in type 2 diabetes - Addendum to commission H20-04]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermal ablation of the duodenal mucosa in type 2 diabetes - Assessment according to §137h Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic surgery in patients with middle ear conditions]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic spine surgery for disc disease and lumbar spinal stenosis]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic mucosectomy for the treatment of sessile polyps ]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Endoscopic mucosal resection (EMR) and endoscopic mucosal dissection (EMD) in superficial gastrointestinal tumors]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic full-thickness resection of colorectal lesions]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic full thickness resection of colorectal lesions]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endoscopic anti-reflux mucosectomy, ARMS]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptabilityy]